Immunovant Statistics
Share Statistics
Immunovant has 146.78M shares outstanding. The number of shares has increased by 1.03% in one year.
| Shares Outstanding | 146.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.29% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 62.27M |
| Failed to Deliver (FTD) Shares | 273 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 12.63M, so 8.61% of the outstanding shares have been sold short.
| Short Interest | 12.63M |
| Short % of Shares Out | 8.61% |
| Short % of Float | 20.29% |
| Short Ratio (days to cover) | 13.9 |
Valuation Ratios
The PE ratio is -16.83 and the forward PE ratio is -9.66.
| PE Ratio | -16.83 |
| Forward PE | -9.66 |
| PS Ratio | 0 |
| Forward PS | 103.7 |
| PB Ratio | 7.07 |
| P/FCF Ratio | -20.34 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Immunovant Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.7, with a Debt / Equity ratio of 0.
| Current Ratio | 13.7 |
| Quick Ratio | 13.7 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.02 |
| Cash Flow / Debt | -1552.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.42% and return on capital (ROIC) is -45.85%.
| Return on Equity (ROE) | -0.42% |
| Return on Assets (ROA) | -0.39% |
| Return on Capital (ROIC) | -45.85% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.25M |
| Employee Count | 207 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 567.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -45.78% in the last 52 weeks. The beta is 0.71, so Immunovant 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | -45.78% |
| 50-Day Moving Average | 27.09 |
| 200-Day Moving Average | 28.6 |
| Relative Strength Index (RSI) | 30.98 |
| Average Volume (20 Days) | 870.36K |
Income Statement
| Revenue | n/a |
| Gross Profit | -231.00K |
| Operating Income | -282.71M |
| Net Income | -259.34M |
| EBITDA | -269.98M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.88 |
Balance Sheet
The company has 635.37M in cash and 138.00K in debt, giving a net cash position of 635.23M.
| Cash & Cash Equivalents | 635.37M |
| Total Debt | 138.00K |
| Net Cash | 635.23M |
| Retained Earnings | -825.68M |
| Total Assets | 515.71M |
| Working Capital | 440.72M |
Cash Flow
In the last 12 months, operating cash flow was -214.23M and capital expenditures -360.00K, giving a free cash flow of -214.59M.
| Operating Cash Flow | -214.23M |
| Capital Expenditures | -360.00K |
| Free Cash Flow | -214.59M |
| FCF Per Share | -1.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IMVT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.21% |
| FCF Yield | -6.38% |
Analyst Forecast
The average price target for IMVT is $47, which is 105.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $47 |
| Price Target Difference | 105.2% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 28.95 |
| Piotroski F-Score | 3 |